Download PDF
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2016; 06(03): 16-20
DOI: 10.1055/s-0040-1708655
Original Article

Comparision of efficacy of local administration of contractubex & corticosteroids for hypertrophic scar in maxillofacial region

Muralee Mohan
1   Professor, Department of Oral & Maxillofacial Surgery, A.B. Shetty Memorial Institute of Dental Science, Nitte University, Mangalore, Karnataka, India
,
B. Rajendra Prasad
2   Principal & Dean, Department of Oral & Maxillofacial Surgery, A.B. Shetty Memorial Institute of Dental Science, Nitte University, Mangalore, Karnataka, India
,
S. M. Sharma
3   Professor & HOD Department of Oral & Maxillofacial Surgery, A.B. Shetty Memorial Institute of Dental Science, Nitte University, Mangalore, Karnataka, India
,
Tripthi Shetty
4   Senior lecturer, Department of Oral & Maxillofacial Surgery, A.B. Shetty Memorial Institute of Dental Science, Nitte University, Mangalore, Karnataka, India
,
Ashay Shah
5   Junior Resident, Department of Oral & Maxillofacial Surgery, A.B. Shetty Memorial Institute of Dental Science, Nitte University, Mangalore, Karnataka, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Hypertrophic scarring following surgical procedures & trauma are a great concern for patients and a challenging problem for clinicians. The therapeutic management of hypertrophic scars is a problem that has not yet been satisfactorily solved. Contractubex® ointment and intra lesional injection of corticosteroids have been used effectively for treatment and prevention of hypertrophic scars. However very few data is available to determine the efficacy of Contractubex® ointment and intra lesional injection of corticosteroids for the treatment of hypertrophic scar. Two study groups were made with 10 patients in each group. Patients in Group 1 treated with Contractubex® and patients in Group 2 treated with intra lesional corticosteroid (Triamcinolone acetonide). Scar was analyzed with Vancouver Scar Scale (VSS) at 2 weeks, 6 weeks and 12 weeks. The collected data was statistically analyzed. We found that the difference between before and after treatment scores for each of the groups was statistically significant (p < 0.05). The mean of the before and after treatment difference for the Group 1 (Contractubex® ) was 4.7 while that of group 2 (Corticosteroids) was 2.8. This demonstrated a significant superiority of the Contractubex® treatment compared to corticosteroid treatment. The difference between treatment responses for both the groups was statistically significant (p < 0.05). Excellent to good responses were reported in 90% of the Group 1 (Contractubex®) patients and 30% of Group 2 (Corticosteroids).

Keywords

TGF-β - PDGF - Glycosaminoglycan


Publication History

Received: 02 December 2014

Accepted: 10 August 2016

Article published online:
22 April 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Peacock Jr EE, Madden JW, Trier WC. Biologic basis for the treatment of keloids and hypertrophic scars. South Med J. 1970; 63(7): 755–60.
  • 2 Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch dermatol Res. 2006; 297(10): 433-38.
  • 3 Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg. 2006; 8(6): 362-68.
  • 4 BS, Atiyeh. Nonsurgical management of hypertrophic scars: evidencebased therapies, standard practices, and emerging methods. Aesthetic Plast Surg. 2007; 31(5): 468-492.
  • 5 Ho WS, Ying SY, Chan PC. Use of onion extract, heparin, allantoin gel in prevention of scarring in Chinese patients having laser removal of tattoos: a prospective randomized controlled trial. Dermatology surg. 2006; 32(7): 891-96.
  • 6 Lorena UlhôaAraújoI, Andrea Grabe-GuimarãesI, Vanessa Carla Furtado MosqueiraI, Claudia Martins Carneiro. Profile of wound healing process induced by allantoin. ActaCirúrgicaBrasileira. 2010; 25(5): 460-66.
  • 7 Dolores Wolfram, Alexander Tzankov, Petra. Hypertrophic Scars and Keloids:A Review of Their Pathophysiology, Risk Factors, and Therapeutic Management. Dermatol Surg. 2009; 35(2): 171-181.
  • 8 Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. J Burn Care Rehabil. 1995; 16(5): 535-8.
  • 9 Lewis W H, Sun KK. Hypertrophic scar: a genetic hypothesis. Burns. 1990; 16(3): 176-78.
  • 10 Hans Korting, Tatiana Pavicic, Thomas Ruzicka, Marc Jeschke. Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Mol Med. 2011; 17(1-2): 113-25.
  • 11 Cohen IK, McCoy BJ, Mohanakumar T, Diegelmann RF. Immunoglobulin, complement, and histocompatibility antigen studies in keloid patients. PlastReconstr Surg. 1979; 63(5): 689-95.
  • 12 J. Beuth, N. Hunzelmann, R. Van Leendert, R. Basten, M. Noehle and B. Schneider. Safety and Efficacy of Local Administration of Contractubex® to Hypertrophic Scars in Comparison to Corticosteroid Treatment. Results of a Multicenter, Comparative Epidemiological Cohort Study in Germany. IN VIVO. 2006; 20(2): 277-284.